Search

Your search keyword '"Fung, Chunkit"' showing total 332 results
Start Over Author "Fung, Chunkit"
332 results on '"Fung, Chunkit"'

2. AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease.

Author

Mohile, Supriya, Blaum, Caroline, Abadir, Peter, Dale, William, Forman, Daniel, Fung, Chunkit, Holmes, Holly, Moslehi, Javid, Mustian, Karen, Rich, Michael, and Whitson, Heather

Subjects
aging, cancer, cardiotoxicity, cardiovascular disease, Aged, Cardiovascular Diseases, Geriatrics, Humans, National Institute on Aging (U.S.), Neoplasms, Risk Factors, United States
Abstract

This report summarizes the presentations, discussions, and recommendations of the most recent American Geriatrics Society and National Institute on Aging research conference, Cancer and Cardiovascular Disease, on October 18-19, 2021. The purpose of this virtual meeting was to address the interface between cancer and heart disease, which are the two leading causes of death among older Americans. Age-related physiologic changes are implicated in the pathogenesis of both conditions. Emerging data suggest that cancer-related cardiovascular disease (CVD) involves disrupted cell signaling and cellular senescence. The risk factors for CVD are also risk factors for cancer and an increased likelihood of cancer death, and people who have both cancer and CVD do more poorly than those who have only cancer or only CVD. Issues addressed in this bench-to-bedside conference include mechanisms of cancer and CVD co-development in older adults, cardiotoxic effects of cancer therapy, and management of comorbid cancer and CVD. Presenters discussed approaches to ensure equitable access to clinical trials and health care for diverse populations of adults with CVD and cancer, mechanisms of cancer therapy cardiotoxicity, and management of comorbid CVD and cancer, including the role of patient values and preferences in treatment decisions. Workshop participants identified many research gaps and questions that could lead to an enhanced understanding of comorbid CVD and cancer and to better and more equitable management strategies.

Published
2022

5. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Author

Sanchez, Victoria A., primary, Dinh, Paul C., additional, Monahan, Patrick O., additional, Althouse, Sandra, additional, Rooker, Jennessa, additional, Sesso, Howard D., additional, Dolan, M. Eileen, additional, Weinzerl, Mandy, additional, Feldman, Darren R., additional, Fung, Chunkit, additional, Einhorn, Lawrence H., additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2024
Full Text
View/download PDF

8. A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).

Author

Kilari, Deepak, primary, Kadambi, Sindhuja G, additional, Baran, Andrea M., additional, Zittel, Jason, additional, Burfeind, John D., additional, Messing, Edward M., additional, Van Veldhuizen, Peter J., additional, Bylow, Kathryn A., additional, Sahasrabudhe, Deepak M., additional, Mohile, Supriya Gupta, additional, and Fung, Chunkit, additional

Published
2024
Full Text
View/download PDF

10. Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report.

Author

Fitzgerald, Bryan P., Magnuson, Allison, and Fung, Chunkit

Subjects
MALE breast cancer, PROSTATE cancer patients, PROGESTERONE receptors, PROSTATE-specific antigen, ESTROGEN receptors, PROSTATE cancer, HORMONE receptor positive breast cancer
Abstract

BACKGROUND: Concurrent breast and prostate cancers in male patients is considerably rare. The first-line treatments for estrogen receptor (ER)-positive, progesterone receptor (PR)-positive breast cancer and prostate cancer include hormonal therapy, albeit they target different hormonal pathways. DISCUSSION: We present an 81-year-old man with concurrent stage IIB ER-positive, PR-positive breast cancer and metastatic prostate cancer who initially received letrozole and leuprolide. After concerns for progression of his breast cancer while receiving letrozole, the patient’s therapy was switched to exemestane, a steroidal structurally different aromatase inhibitor. His testosterone and prostate-specific antigen levels increased after the initiation of treatment with exemestane, and subsequently decreased after the discontinuation of exemestane treatment. CONCLUSION: Our case report shows that treatment with exemestane should be avoided in male patients with concurrent breast and prostate cancers as a result of the progression of prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024

11. High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

Author

Peppone, Luke J., Kleckner, Amber S., Fung, Chunkit, Puzas, J. Edward, Reschke, Jennifer E., Culakova, Eva, Inglis, Julia, Kamen, Charles, Friedberg, Jonathan W., Janelsins, Michelle, Mustian, Karen, Heckler, Charles E., and Mohile, Supriya

Subjects
FEMUR neck, ANDROGEN deprivation therapy, PROSTATE cancer patients, BONE density, DUAL-energy X-ray absorptiometry, BONE growth, TERIPARATIDE, ANDROGEN receptors
Abstract

Background: Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However, ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective interventions for ADT‐induced bone loss are limited. Methods: A phase 2 randomized controlled trial investigated the feasibility, safety, and preliminary efficacy of high‐dose weekly vitamin D (HDVD, 50,000 IU/week) versus placebo for 24 weeks in patients with prostate cancer receiving ADT, with all subjects receiving 600 IU/day vitamin D and 1000 mg/day calcium. Participants were ≥60 years (mean years, 67.7), had a serum 25‐hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months. At baseline and after intervention, dual‐energy x‐ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured. Results: The HDVD group (N = 29) lost 1.5% BMD at the total hip vs. 4.1% for the low‐dose group (N = 30; p =.03) and 1.7% BMD at the femoral neck vs. 4.4% in the low‐dose group (p =.06). Stratified analyses showed that, for those with baseline 25‐hydroxyvitamin D level <27 ng/mL, the HDVD group lost 2.3% BMD at the total hip vs 7.1% for the low‐dose group (p <.01). Those in the HDVD arm showed significant changes in parathyroid hormone (p <.01), osteoprotegerin (p < 0.01), N‐terminal telopeptide of type 1 collagen (p < 0.01) and C‐terminal telopeptide of type 1 collagen (p < 0.01). No difference in adverse events or toxicity was noted between the groups. Conclusions: HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25‐hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT. Patients with prostate cancer on androgen deprivation therapy often suffer rapid bone loss during the initiation of treatment. Supplementation with high‐dose vitamin D (50,000 IU/week plus 800 IU/day) significantly and safely decreased the amount of bone loss compared with vitamin D supplementation using the recommended daily allowance (800 IU/day). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

13. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

Author

Ardeshirrouhanifard, Shirin, Fossa, Sophie D., Huddart, Robert, Monahan, Patrick O., Fung, Chunkit, Song, Yiqing, Dolan, M. Eileen, Feldman, Darren R., Hamilton, Robert J., Vaughn, David, Martin, Neil E., Kollmannsberger, Christian, Dinh, Paul, Einhorn, Lawrence, Frisina, Robert D., and Travis, Lois B.

Published
2022
Full Text
View/download PDF

14. Supplemental Materials from Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms

Author

El Charif, Omar, primary, Mapes, Brandon, primary, Trendowski, Matthew R., primary, Wheeler, Heather E., primary, Wing, Claudia, primary, Dinh, Paul C., primary, Frisina, Robert D., primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Gamazon, Eric R., primary, Cox, Nancy J., primary, Huddart, Robert, primary, Ardeshir-Rouhani-Fard, Shirin, primary, Monahan, Patrick, primary, Fossa, Sophie D., primary, Einhorn, Lawrence H., primary, Travis, Lois B., primary, and Dolan, M. Eileen, primary

Published
2023
Full Text
View/download PDF

15. Impact of Pain and Adverse Health Outcomes on Long-term U.S. Testicular Cancer Survivors

Author

Dinh, Paul C, primary, Monahan, Patrick O, additional, Fosså, Sophie D, additional, Sesso, Howard D, additional, Feldman, Darren R, additional, Dolan, M Eileen, additional, Nevel, Kathryn, additional, Kincaid, John, additional, Vaughn, David J, additional, Martin, Neil E, additional, Sanchez, Victoria A, additional, Einhorn, Lawrence H, additional, Frisina, Robert, additional, Fung, Chunkit, additional, Kroenke, Kurt, additional, and Travis, Lois B, additional

Published
2023
Full Text
View/download PDF

20. Impact of pain and adverse health outcomes on long-term US testicular cancer survivors.

Author

Dinh, Paul C, Monahan, Patrick O, Fosså, Sophie D, Sesso, Howard D, Feldman, Darren R, Dolan, M Eileen, Nevel, Kathryn, Kincaid, John, Vaughn, David J, Martin, Neil E, Sanchez, Victoria A, Einhorn, Lawrence H, Frisina, Robert, Fung, Chunkit, Kroenke, Kurt, and Travis, Lois B

Subjects
TESTICULAR cancer, CANCER survivors, PERIPHERAL vascular diseases, PAIN, NEURALGIA, MENTAL health, FUNCTIONAL status
Abstract

Background No study has quantified the impact of pain and other adverse health outcomes on global physical and mental health in long-term US testicular cancer survivors or evaluated patient-reported functional impairment due to pain. Methods Testicular cancer survivors given cisplatin-based chemotherapy completed validated surveys, including Patient-Reported Outcomes Measurement Information System v1.2 global physical and mental health, Patient-Reported Outcomes Measurement Information System pain questionnaires, and others. Multivariable linear regression examined relationships between 25 adverse health outcomes with global physical and mental health and pain-interference scores. Adverse health outcomes with a β ^  of more than 2 are clinically important and reported below. Results Among 358 testicular cancer survivors (median age = 46 years, interquartile range [IQR] = 38–53 years; median time since chemotherapy = 10.7 years, IQR = 7.2–16.0 years), median adverse health outcomes number was 5 (IQR = 3–7). A total of 12% testicular cancer survivors had 10 or more adverse health outcomes, and 19% reported chemotherapy-induced neuropathic pain. Increasing adverse health outcome numbers were associated with decreases in physical and mental health (P  <  .0001 each). In multivariable analyses, chemotherapy-induced neuropathic pain (⁠ β ^ = −3.72; P  =  .001), diabetes (⁠ β ^ = −4.41; P  =  .037), obesity (⁠ β ^ = −2.01; P  =  .036), and fatigue (⁠ β ^ = −8.58; P  <  .0001) were associated with worse global mental health, while being married or living as married benefited global mental health (⁠ β ^  = 3.63; P  =  .0006). Risk factors for pain-related functional impairment included lower extremity location (⁠ β ^  = 2.15; P  =  .04) and concomitant peripheral artery disease (⁠ β ^  = 4.68; P  <  .001). Global physical health score reductions were associated with diabetes (⁠ β ^ = −3.81; P  =  .012), balance or equilibrium problems (⁠ β ^ = −3.82; P  =  .003), cognitive dysfunction (⁠ β ^ = −4.43; P  <  .0001), obesity (⁠ β ^ = −3.09; P  <  .0001), peripheral neuropathy score (⁠ β ^ = −2.12; P  <  .0001), and depression (⁠ β ^ = −3.17; P  <  .0001). Conclusions Testicular cancer survivors suffer adverse health outcomes that negatively impact long-term global mental health, global physical health, and pain-related functional status. Clinically important factors associated with worse physical and mental health identify testicular cancer survivors requiring closer monitoring, counseling, and interventions. Chemotherapy-induced neuropathic pain must be addressed, given its detrimental impact on patient-reported functional status and mental health 10 or more years after treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Coverage for evidence-based cancer survivorship care services

Author

Blaes, Anne H., primary, Abu-Khalaf, Maysa M., additional, Bender, Catherine M., additional, Dent, Susan F., additional, Fung, Chunkit, additional, Smith, Sophia K., additional, Watson, Samantha, additional, Katta, Sweatha, additional, Merrill, Janette K., additional, and Hudson, Shawna V., additional

Published
2023
Full Text
View/download PDF

23. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score

Author

Sesso, Howard D., Beard, Clair J., Curreri, Stephanie, Travis, Lois B., Einhorn, Lawrence H., Brames, Mary Jacqueline, Norton, Kelli, Feldman, Darren R., Oeffinger, Kevin C., Jacobsen, Erin, Silber, Deborah, Hamilton, Rob, Anson-Cartwright, Lynn, Cox, Nancy J., Dolan, M. Eileen, Vaughn, David J., Jacobs, Linda, Panzer, Sarah Lena, Pucci, Donna, Baker, Debbie, Casaceli, Cindy, Fung, Chunkit, Johnson, Eileen, Sahasrabudhe, Deepak, Frisina, Robert D., Bosl, George, Fossa, Sophie D., Gospodarowicz, Mary, Robison, Leslie L., Lipshultz, Steven E., Ardeshir-Rouhani-Fard, Shirin, Monahan, Patrick, Williams, Annalynn M., Hamilton, Robert J., Cook, Ryan, and Zaid, Mohammad Abu

Published
2018
Full Text
View/download PDF

24. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy

Author

Sanchez, Victoria A., primary, Shuey, Megan M., additional, Dinh, Paul C., additional, Monahan, Patrick O., additional, Fosså, Sophie D., additional, Sesso, Howard D., additional, Dolan, M. Eileen, additional, Einhorn, Lawrence H., additional, Vaughn, David J., additional, Martin, Neil E., additional, Feldman, Darren R., additional, Kroenke, Kurt, additional, Fung, Chunkit, additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2023
Full Text
View/download PDF

25. Novel Biomarkers Of Treatment-Induced Muscle Damage, Exercise And Fatigue: An RCT In Breast Cancer Patients: 3540 Board #361 May 29 2:30 PM - 4:00 PM

Author

Mustian, Karen M., Lin, Po-Ju, Culakova, Eva, Colasurdo, Ann, Dunne, Richard F., Fung, Chunkit, Gilmore, Nikesha J., Heckler, Charles E., Inglis, Julia E., Janelsins, Michelle C., Kamen, Charles S., Kleckner, Amber S., Kleckner, Ian R., Loh, Kah Poh, Lopez, Gilberto, Peppone, Luke J., Porto, Michelle, Ramsdale, Erika, and Morrow, Gary

Published
2020
Full Text
View/download PDF

27. Supplementary Table S2 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

Author

Wheeler, Heather E., primary, Gamazon, Eric R., primary, Frisina, Robert D., primary, Perez-Cervantes, Carlos, primary, El Charif, Omar, primary, Mapes, Brandon, primary, Fossa, Sophie D., primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Beard, Clair J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Kim, Jeri, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Ardeshir-Rouhani-Fard, Shirin, primary, Einhorn, Lawrence H., primary, Cox, Nancy J., primary, Dolan, M. Eileen, primary, and Travis, Lois B., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure S4 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

Author

Wheeler, Heather E., primary, Gamazon, Eric R., primary, Frisina, Robert D., primary, Perez-Cervantes, Carlos, primary, El Charif, Omar, primary, Mapes, Brandon, primary, Fossa, Sophie D., primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Beard, Clair J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Kim, Jeri, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Ardeshir-Rouhani-Fard, Shirin, primary, Einhorn, Lawrence H., primary, Cox, Nancy J., primary, Dolan, M. Eileen, primary, and Travis, Lois B., primary

Published
2023
Full Text
View/download PDF

29. Supplementary data from Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms

Author

El Charif, Omar, primary, Mapes, Brandon, primary, Trendowski, Matthew R., primary, Wheeler, Heather E., primary, Wing, Claudia, primary, Dinh, Paul C., primary, Frisina, Robert D., primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Gamazon, Eric R., primary, Cox, Nancy J., primary, Huddart, Robert, primary, Ardeshir-Rouhani-Fard, Shirin, primary, Monahan, Patrick, primary, Fossa, Sophie D., primary, Einhorn, Lawrence H., primary, Travis, Lois B., primary, and Dolan, M. Eileen, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Material from Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy

Author

Trendowski, Matthew R., primary, El-Charif, Omar, primary, Ratain, Mark J., primary, Monahan, Patrick, primary, Mu, Zepeng, primary, Wheeler, Heather E., primary, Dinh, Paul C., primary, Feldman, Darren R., primary, Ardeshir-Rouhani-Fard, Shirin, primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Hannigan, Robyn, primary, Strathmann, Frederick, primary, Einhorn, Lawrence H., primary, Fossa, Sophie D., primary, Travis, Lois B., primary, and Dolan, M. Eileen, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Author

Dolan, M. Eileen, primary, El Charif, Omar, primary, Wheeler, Heather E., primary, Gamazon, Eric R., primary, Ardeshir-Rouhani-Fard, Shirin, primary, Monahan, Patrick, primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Beard, Clair J., primary, Fung, Chunkit, primary, Kim, Jeri, primary, Fossa, Sophie D., primary, Hertz, Daniel L, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Einhorn, Lawrence H., primary, Cox, Nancy J., primary, and Travis, Lois B., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

Author

Trendowski, Matthew R., primary, Wheeler, Heather E., primary, El-Charif, Omar, primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Einhorn, Lawrence H., primary, Travis, Lois B., primary, and Dolan, M. Eileen, primary

Published
2023
Full Text
View/download PDF

35. Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors

Author

Lin, Po-Ju, primary, Altman, Brian J., additional, Gilmore, Nikesha J., additional, Loh, Kah Poh, additional, Dunne, Richard F., additional, Bautista, Javier, additional, Fung, Chunkit, additional, Janelsins, Michelle C., additional, Peppone, Luke J., additional, Melnik, Marianne K., additional, Gococo, Kim O., additional, Messino, Michael J., additional, and Mustian, Karen M., additional

Published
2023
Full Text
View/download PDF

38. Biotoxicity of Chemotherapy

Author

Fung, Chunkit, Pandya, Kishan J., Brady, Luther W., Series editor, Heilmann, Hans-Peter, Series editor, Molls, Michael, Series editor, Nieder, Carsten, Series editor, Rubin, Philip, editor, Constine, Louis S., editor, and Marks, Lawrence B., editor

Published
2014
Full Text
View/download PDF

47. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study

Author

Shah, Amishi Y., Karam, Jose A., Malouf, Gabriel G., Rao, Priya, Lim, Zita D., Jonasch, Eric, Xiao, Lianchun, Gao, Jianjun, Vaishampayan, Ulka N., Heng, Daniel Y., Plimack, Elizabeth R., Guancial, Elizabeth A., Fung, Chunkit, Lowas, Stefanie R., Tamboli, Pheroze, Sircar, Kanishka, Matin, Surena F., Kimryn Rathmell, W., Wood, Christopher G., and Tannir, Nizar M.

Published
2017
Full Text
View/download PDF

50. Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.

Author

Shuey, Megan, primary, Sanchez, Victoria, additional, Dinh, Paul C., additional, Monahan, Patrick O., additional, Sesso, Howard D., additional, Dolan, Mary Eileen, additional, Fossa, Sophie D., additional, Einhorn, Lawrence H., additional, Vaughn, David J., additional, Martin, Neil E., additional, Fung, Chunkit, additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results